Cargando…
Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
BACKGROUND: The incretin effect is impaired in patients with type 2 diabetes. AIM: To assess the relation between the incretin hormone GLP-1 and the prediabetic subtypes: impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and the combined IFG/IGT to investigate whether a low GLP-1 res...
Autores principales: | Larsen, Matthias Ploug, Torekov, Signe Sørensen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610892/ https://www.ncbi.nlm.nih.gov/pubmed/29082261 http://dx.doi.org/10.1155/2017/7583506 |
Ejemplares similares
-
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017) -
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
por: Viljoen, Adie, et al.
Publicado: (2023) -
Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011) -
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017) -
Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)